Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA

Science Translational Medicine

Volumn 8, Issue 364, 2016, Pages

  Scherer, Florian ^a   Kurtz, David M ^a,b   Newman, Aaron M ^a   Stehr, Henning ^c   Craig, Alexander F M ^a   Esfahani, Mohammad Shahrokh ^a   Lovejoy, Alexander F ^a,c,d,e   Chabon, Jacob J ^a   Klass, Daniel M ^a,c,e   Liu, Chih Long ^a   Zhou, Li ^c   Glover, Cynthia ^a   Visser, Brendan C ^d   Poultsides, George A ^d   Advani, Ranjana H ^a   Maeda, Lauren S ^a   Gupta, Neel K ^a   Levy, Ronald ^a   Ohgami, Robert S ^a   Kunder, Christian A ^a   Diehn, Maximilian ^a,c,d   Alizadeh, Ash A ^a,c   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN; TUMOR MARKER;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL FEATURE; CLONAL EVOLUTION; CONTROLLED STUDY; EVOLUTION; FOLLICULAR LYMPHOMA; GENETIC HETEROGENEITY; GENOME EVOLUTION; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MINIMAL RESIDUAL DISEASE; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CLASSIFICATION; ADULT; AGED; ALGORITHM; B CELL LYMPHOMA; BIOPSY; BLOOD; CELL FREE SYSTEM; CHEMISTRY; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOMARKERS, TUMOR; BIOPSY; CELL-FREE SYSTEM; CIRCULATING TUMOR DNA; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULINS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84996489062     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aai8545     Document Type: Article

References (82)

1. M. P. Menon, S. Pittaluga, E. S. Jaffe, The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. Cancer J. 18, 411-420 (2012).
2. M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren, E. Lengfelder, M. Reiser, C. Nickenig, M. Clemens, N. Peter, C. Bokemeyer, H. Eimermacher, A. Ho, M. Hoffmann, R. Mertelsmann, L. Trümper, L. Balleisen, R. Liersch, B. Metzner, F. Hartmann, B. Glass, V. Poeschel, N. Schmitz, C. Ruebe, A. C. Feller, M. Loeffler; German High-Grade Non- Hodgkin Lymphoma Study, Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 9, 105-116 (2008).
3. B. Coiffier, E. Lepage, J. Brière, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, F. Reyes, P. Lederlin, C. Gisselbrecht, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
4. A. Younes, Prognostic significance of diffuse large B-cell lymphoma cell of origin: Seeing the forest and the trees. J. Clin. Oncol. 33, 2835-2836 (2015).
5. M. A. Shipp, D. P. Harrington, J. R. Anderson, J. O. Armitage, G. Bonadonna, G. Brittinger, F. Cabanillas, G. P. Canellos, B. Coiffier, J. M. Connors, R. A. Cowan, D. Crowther, S. Dahlberg, M. Engelhard, R. I. Fisher, C. Gisselbrecht, S. J. Horning, E. Lepage, T. A. Lister, J. H. Meerwaldt, E. Montserrat, N. I. Nissen, M. M. Oken, B. A. Peterson, C. Tondini, W. A. Velasquez, B. Y. Yeap, A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 329, 987-994 (1993).
6. C. A. Thompson, H. Ghesquieres, M. J. Maurer, J. R. Cerhan, P. Biron, S. M. Ansell, C. Chassagne-Clement, D. J. Inwards, T. Gargi, P. B. Johnston, E. Nicolas-Virelizier, W. R. Macon, M. Peix, I. N. Micallef, C. Sebban, G. S. Nowakowski, L. F. Porrata, G. J. Weiner, T. E. Witzig, T. M. Habermann, B. K. Link, Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J. Clin. Oncol. 32, 3506-3512 (2014).
7. C. H. Moskowitz, H. Schöder, J. Teruya-Feldstein, C. Sima, A. Iasonos, C. S. Portlock, D. Straus, A. Noy, M. L. Palomba, O. A. O'Connor, S. Horwitz, S. A. Weaver, J. L. Meikle, D. A. Filippa, J. F. Caravelli, P. A. Hamlin, A. D. Zelenetz, Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J. Clin. Oncol. 28, 1896-1903 (2010).
8. T. C. El-Galaly, L. H. Jakobsen, M. Hutchings, P. de Nully Brown, H. Nilsson-Ehle, E. Székely, K. J. Mylam, V. Hjalmar, H. E. Johnsen, M. Bøgsted, M. Jerkeman, Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: A Danish-Swedish population-based study. J. Clin. Oncol. 33, 3993-3998 (2015).
9. A. A. Alizadeh, M. B. Eisen, R. E. Davis, C. Ma, I. S. Lossos, A. Rosenwald, J. C. Boldrick, H. Sabet, T. Tran, X. Yu, J. I. Powell, L. Yang, G. E. Marti, T. Moore, J. Hudson Jr., L. Lu, D. B. Lewis, R. Tibshirani, G. Sherlock, W. C. Chan, T. C. Greiner, D. D. Weisenburger, J. O. Armitage, R. Warnke, R. Levy, W. Wilson, M. R. Grever, J. C. Byrd, D. Botstein, P. O. Brown, L. M. Staudt, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511 (2000).
10. G. Lenz, G. W. Wright, N. C. T. Emre, H. Kohlhammer, S. S. Dave, R. E. Davis, S. Carty, L. T. Lam, A. L. Shaffer, W. Xiao, J. Powell, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, R. D. Gascoyne, J. M. Connors, E. Campo, E. S. Jaffe, J. Delabie, E. B. Smeland, L. M. Rimsza, R. I. Fisher, D. D. Weisenburger, W. C. Chan, L. M. Staudt, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. U.S.A. 105, 13520-13525 (2008).
11. A. Rosenwald, G. Wright, W. C. Chan, J. M. Connors, E. Campo, R. I. Fisher, R. D. Gascoyne, H. K. Muller-Hermelink, E. B. Smeland, J. M. Giltnane, E. M. Hurt, H. Zhao, L. Averett, L. Yang, W. H. Wilson, E. S. Jaffe, R. Simon, R. D. Klausner, J. Powell, P. L. Duffey, D. L. Longo, T. C. Greiner, D. D. Weisenburger, W. G. Sanger, B. J. Dave, J. C. Lynch, J. Vose, J. O. Armitage, E. Montserrat, A. López-Guillermo, T. M. Grogan, T. P. Miller, M. LeBlanc, G. Ott, S. Kvaloy, J. Delabie, H. Holte, P. Krajci, T. Stokke, L. M. Staudt; Lymphoma/Leukemia Molecular Profiling Project, The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937-1947 (2002).
12. W. H. Wilson, R. M. Young, R. Schmitz, Y. Yang, S. Pittaluga, G. Wright, C.-J. Lih, P. M. Williams, A. L. Shaffer, J. Gerecitano, S. de Vos, A. Goy, V. P. Kenkre, P. M. Barr, K. A. Blum, A. Shustov, R. Advani, N. H. Fowler, J. M. Vose, R. L. Elstrom, T. M. Habermann, J. C. Barrientos, J. McGreivy, M. Fardis, B. Y. Chang, F. Clow, B. Munneke, D. Moussa, D. M. Beaupre, L. M. Staudt, Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21, 922-926 (2015).
13. C. Thieblemont, J. Briere, N. Mounier, H.-U. Voelker, W. Cuccuini, E. Hirchaud, A. Rosenwald, A. Jack, C. Sundstrom, S. Cogliatti, P. Trougouboff, L. Boudova, L. Ysebaert, J. Soulier, C. Chevalier, D. Bron, N. Schmitz, P. Gaulard, R. Houlgatte, C. Gisselbrecht, The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study. J. Clin. Oncol. 29, 4079-4087 (2011).
14. G. S. Nowakowski, B. LaPlant, W. R. Macon, C. B. Reeder, J. M. Foran, G. D. Nelson, C. A. Thompson, C. E. Rivera, D. J. Inwards, I. N. Micallef, P. B. Johnston, L. F. Porrata, S. M. Ansell, R. D. Gascoyne, T. M. Habermann, T. E. Witzig, Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase II study. J. Clin. Oncol. 33, 251-257 (2015).
15. K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, W. H. Wilson, Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113, 6069-6076 (2009).
16. D. W. Scott, G. W. Wright, P. M. Williams, C.-J. Lih, W. Walsh, E. S. Jaffe, A. Rosenwald, E. Campo, W. C. Chan, J. M. Connors, E. B. Smeland, A. Mottok, R. M. Braziel, G. Ott, J. Delabie, R. R. Tubbs, J. R. Cook, D. D. Weisenburger, T. C. Greiner, B. J. Glinsmann-Gibson, K. Fu, L. M. Staudt, R. D. Gascoyne, L. M. Rimsza, Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 1214-1217 (2014).
17. C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Müller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, Z. Pan, P. Farinha, L. M. Smith, B. Falini, A. H. Banham, A. Rosenwald, L. M. Staudt, J. M. Connors, J. O. Armitage, W. C. Chan, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275-282 (2004).
18. G. Salles, D. de Jong, W. Xie, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, M. Calaminici, B. Sander, C. Thorns, E. Campo, T. Molina, A. Lee, M. Pfreundschuh, S. Horning, A. Lister, L. H. Sehn, J. Raemaekers, A. Hagenbeek, R. D. Gascoyne, E. Weller, Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117, 7070-7078 (2011).
19. A. D. Zelenetz, L. I. Gordon, W. G. Wierda, J. S. Abramson, R. H. Advani, C. B. Andreadis, N. Bartlett, J. C. Byrd, L. E. Fayad, R. I. Fisher, M. J. Glenn, T. M. Habermann, N. Lee Harris, F. Hernandez-Ilizaliturri, R. T. Hoppe, S. M. Horwitz, M. S. Kaminski, C. R. Kelsey, Y. H. Kim, S. Krivacic, A. S. LaCasce, M. Lunning, A. Nademanee, P. Porcu, O. Press, R. Rabinovitch, N. Reddy, E. Reid, K. Roberts, A. A. Saad, L. Sokol, L. J. Swinnen, J. M. Vose, J. Yahalom, N. Zafar, M. Dwyer, H. Sundar, Diffuse large B-cell lymphoma version 1.2016. J. Natl. Compr. Cancer Network 14, 196-231 (2016).
20. B. K. Link, M. J. Maurer, G. S. Nowakowski, S. M. Ansell, W. R. Macon, S. I. Syrbu, S. L. Slager, C. A. Thompson, D. J. Inwards, P. B. Johnston, J. P. Colgan, T. E. Witzig, T. M. Habermann, J. R. Cerhan, Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J. Clin. Oncol. 31, 3272-3278 (2013).
21. N. D. Wagner-Johnston, B. K. Link, M. Byrtek, K. L. Dawson, J. Hainsworth, C. R. Flowers, J. W. Friedberg, N. L. Bartlett, Outcomes of transformed follicular lymphoma in the modern era: A report from the National LymphoCare Study (NLCS). Blood 126, 851-857 (2015).
22. J. Okosun, C. Bödör, J. Wang, S. Araf, C.-Y. Yang, C. Pan, S. Boller, D. Cittaro, M. Bozek, S. Iqbal, J. Matthews, D. Wrench, J. Marzec, K. Tawana, N. Popov, C. O'Riain, D. O'Shea, E. Carlotti, A. Davies, C. H. Lawrie, A. Matolcsy, M. Calaminici, A. Norton, R. J. Byers, C. Mein, E. Stupka, T. A. Lister, G. Lenz, S. Montoto, J. G. Gribben, Y. Fan, R. Grosschedl, C. Chelala, J. Fitzgibbon, Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46, 176-181 (2014).
23. L. Pasqualucci, H. Khiabanian, M. Fangazio, M. Vasishtha, M. Messina, A. B. Holmes, P. Ouillette, V. Trifonov, D. Rossi, F. Tabbò, M. Ponzoni, A. Chadburn, V. V. Murty, G. Bhagat, G. Gaidano, G. Inghirami, S. N. Malek, R. Rabadan, R. Dalla-Favera, Genetics of follicular lymphoma transformation. Cell Rep. 6, 130-140 (2014).
24. M. R. Green, S. Kihira, C. L. Liu, R. V. Nair, R. Salari, A. J. Gentles, J. Irish, H. Stehr, C. Vicente-Dueñas, I. Romero-Camarero, I. Sanchez-Garcia, S. K. Plevritis, D. A. Arber, S. Batzoglou, R. Levy, A. A. Alizadeh, Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. U.S.A. 112, E1116-E1125 (2015).
25. C. Casulo, W. R. Burack, J. W. Friedberg, Transformed follicular non-Hodgkin lymphoma. Blood 125, 40-47 (2015).
26. D. M. Kurtz, M. R. Green, S. V. Bratman, F. Scherer, C. L. Liu, C. A. Kunder, K. Takahashi, C. Glover, C. Keane, S. Kihira, B. Visser, J. Callahan, K. A. Kong, M. Faham, K. S. Corbelli, D. Miklos, R. H. Advani, R. Levy, R. J. Hicks, M. Hertzberg, R. S. Ohgami, M. K. Gandhi, M. Diehn, A. A. Alizadeh, Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125, 3679-3687 (2015).
27. M. Roschewski, K. Dunleavy, S. Pittaluga, M. Moorhead, F. Pepin, K. Kong, M. Shovlin, E. S. Jaffe, L. M. Staudt, C. Lai, S. M. Steinberg, C. C. Chen, J. Zheng, T. D. Willis, M. Faham, W. H. Wilson, Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study. Lancet Oncol. 16, 541-549 (2015).
28. S. V. Bratman, A. M. Newman, A. A. Alizadeh, M. Diehn, Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev. Mol. Diagn. 15, 715-719 (2015).
29. J. J. Chabon, A. D. Simmons, A. F. Lovejoy, M. S. Esfahani, A. M. Newman, H. J. Haringsma, D. M. Kurtz, H. Stehr, F. Scherer, C. A. Karlovich, T. C. Harding, K. A. Durkin, G. A. Otterson, W. T. Purcell, D. R. Camidge, J. W. Goldman, L. V. Sequist, Z. Piotrowska, H. A. Wakelee, J. W. Neal, A. A. Alizadeh, M. Diehn, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun. 7, 11815 (2016).
30. C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang, N. Agrawal, B. R. Bartlett, H. Wang, B. Luber, R. M. Alani, E. S. Antonarakis, N. S. Azad, A. Bardelli, H. Brem, J. L. Cameron, C. C. Lee, L. A. Fecher, G. L. Gallia, P. Gibbs, D. Le, R. L. Giuntoli, M. Goggins, M. D. Hogarty, M. Holdhoff, S.-M. Hong, Y. Jiao, H. H. Juhl, J. J. Kim, G. Siravegna, D. A. Laheru, C. Lauricella, M. Lim, E. J. Lipson, S. K. N. Marie, G. J. Netto, K. S. Oliner, A. Olivi, L. Olsson, G. J. Riggins, A. Sartore-Bianchi, K. Schmidt, I.-M. Shih, S. M. Oba-Shinjo, S. Siena, D. Theodorescu, J. Tie, T. T. Harkins, S. Veronese, T.-L. Wang, J. D. Weingart, C. L. Wolfgang, L. D. Wood, D. Xing, R. H. Hruban, J. Wu, P. J. Allen, C. M. Schmidt, M. A. Choti, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, N. Papadopoulos, L. A. Diaz Jr., Detection of circulating tumor DNA in early- And late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
31. F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, S. A. Szabo, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
32. J. Tie, Y. Wang, C. Tomasetti, L. Li, S. Springer, I. Kinde, N. Silliman, M. Tacey, H.-L. Wong, M. Christie, S. Kosmider, I. Skinner, R. Wong, M. Steel, B. Tran, J. Desai, I. Jones, A. Haydon, T. Hayes, T. J. Price, R. L. Strausberg, L. A. Diaz Jr., N. Papadopoulos, K. W. Kinzler, B. Vogelstein, P. Gibbs, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).
33. A. M. Newman, S. V. Bratman, J. To, J. F. Wynne, N. C. W. Eclov, L. A. Modlin, C. L. Liu, J. W. Neal, H. A. Wakelee, R. E. Merritt, J. B. Shrager, B. W. Loo Jr., A. A. Alizadeh, M. Diehn, An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548-554 (2014).
34. A. M. Newman, A. F. Lovejoy, D. M. Klass, D. M. Kurtz, J. J. Chabon, F. Scherer, H. Stehr, C. L. Liu, S. V. Bratman, C. Say, L. Zhou, J. N. Carter, R. B. West, G. W. Sledge Jr., J. B. Shrager, B. W. Loo Jr., J. W. Neal, H. A. Wakelee, M. Diehn, A. A. Alizadeh, Integrated digital error suppression for improved detection of circulating tumor DNA. Nat. Biotechnol. 34, 547-555 (2016).
35. R. D. Morin, M. Mendez-Lago, A. J. Mungall, R. Goya, K. L. Mungall, R. D. Corbett, N. A. Johnson, T. M. Severson, R. Chiu, M. Field, S. Jackman, M. Krzywinski, D. W. Scott, D. L. Trinh, J. Tamura-Wells, S. Li, M. R. Firme, S. Rogic, M. Griffith, S. Chan, O. Yakovenko, I. M. Meyer, E. Y. Zhao, D. Smailus, M. Moksa, S. Chittaranjan, L. Rimsza, A. Brooks-Wilson, J. J. Spinelli, S. Ben-Neriah, B. Meissner, B. Woolcock, M. Boyle, H. McDonald, A. Tam, Y. Zhao, A. Delaney, T. Zeng, K. Tse, Y. Butterfield, I. Birol, R. Holt, J. Schein, D. E. Horsman, R. Moore, S. J. M. Jones, J. M. Connors, M. Hirst, R. D. Gascoyne, M. A. Marra, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298-303 (2011).
36. R. D. Morin, K. Mungall, E. Pleasance, A. J. Mungall, R. Goya, R. D. Huff, D. W. Scott, J. Ding, A. Roth, R. Chiu, R. D. Corbett, F. C. Chan, M. Mendez-Lago, D. L. Trinh, M. Bolger-Munro, G. Taylor, A. Hadj Khodabakhshi, S. Ben-Neriah, J. Pon, B. Meissner, B. Woolcock, N. Farnoud, S. Rogic, E. L. Lim, N. A. Johnson, S. Shah, S. Jones, C. Steidl, R. Holt, I. Birol, R. Moore, J. M. Connors, R. D. Gascoyne, M. A. Marra, Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122, 1256-1265 (2013).
37. J. Zhang, V. Grubor, C. L. Love, A. Banerjee, K. L. Richards, P. A. Mieczkowski, C. Dunphy, W. Choi, W. Y. Au, G. Srivastava, P. L. Lugar, D. A. Rizzieri, A. S. Lagoo, L. Bernal-Mizrachi, K. P. Mann, C. Flowers, K. Naresh, A. Evens, L. I. Gordon, M. Czader, J. I. Gill, E. D. Hsi, Q. Liu, A. Fan, K. Walsh, D. Jima, L. L. Smith, A. J. Johnson, J. C. Byrd, M. A. Luftig, T. Ni, J. Zhu, A. Chadburn, S. Levy, D. Dunson, S. S. Dave, Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 110, 1398-1403 (2013).
38. J. G. Lohr, P. Stojanov, M. S. Lawrence, D. Auclair, B. Chapuy, C. Sougnez, P. Cruz-Gordillo, B. Knoechel, Y. W. Asmann, S. L. Slager, A. J. Novak, A. Dogan, S. M. Ansell, B. K. Link, L. Zou, J. Gould, G. Saksena, N. Stransky, C. Rangel-Escareño, J. C. Fernandez-Lopez, A. Hidalgo-Miranda, J. Melendez-Zajgla, E. Hernández-Lemus, A. Schwarz-Cruz y Celis, I. Imaz-Rosshandler, A. I. Ojesina, J. Jung, C. S. Pedamallu, E. S. Lander, T. M. Habermann, J. R. Cerhan, M. A. Shipp, G. Getz, T. R. Golub, Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. U.S.A. 109, 3879-3884 (2012).
39. I. S. Lossos, C. Y. Okada, R. Tibshirani, R. Warnke, J. M. Vose, T. C. Greiner, R. Levy, Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 95, 1797-1803 (2000).
40. A. G. Tsai, H. Lu, S. C. Raghavan, M. Muschen, C.-L. Hsieh, M. R. Lieber, Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135, 1130-1142 (2008).
41. Z. Lu, A. G. Tsai, T. Akasaka, H. Ohno, Y. Jiang, A. M. Melnick, H. A. Greisman, M. R. Lieber, BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. Blood 121, 4551-4554 (2013).
42. T. Akasaka, H. Akasaka, C. Ueda, N. Yonetani, Y. Maesako, A. Shimizu, H. Yamabe, S. Fukuhara, T. Uchiyama, H. Ohno, Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavychain fusion gene. J. Clin. Oncol. 18, 510-518 (2000).
43. H. Horn, M. Ziepert, C. Becher, T. F. E. Barth, H. W. Bernd, A. C. Feller, W. Klapper, M. Hummel, H. Stein, M.-L. Hansmann, C. Schmelter, P. Möller, S. Cogliatti, M. Pfreundschuh, N. Schmitz, L. Trumper, R. Siebert, M. Loeffler, A. Rosenwald, G. Ott; German High-Grade Non-Hodgkin Lymphoma Study, MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121, 2253-2263 (2013).
44. D. J. Landsburg, S. D. Nasta, J. Svoboda, J. J. D. Morrissette, S. J. Schuster, 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br. J. Haematol. 166, 369-374 (2014).
45. Y. Oki, M. Noorani, P. Lin, R. E. Davis, S. S. Neelapu, L. Ma, M. Ahmed, M. A. Rodriguez, F. B. Hagemeister, N. Fowler, M. Wang, M. A. Fanale, L. Nastoupil, F. Samaniego, H. J. Lee, B. S. Dabaja, C. C. Pinnix, L. J. Medeiros, Y. Nieto, I. Khouri, L. W. Kwak, F. Turturro, J. E. Romaguera, L. E. Fayad, J. R. Westin, Double hit lymphoma: The MD Anderson Cancer Center clinical experience. Br. J. Haematol. 166, 891-901 (2014).
46. K. Karube, E. Campo, MYC alterations in diffuse large B-cell lymphomas. Semin. Hematol. 52, 97-106 (2015).
47. E. Campo, MYC in DLBCL: Partners matter. Blood 126, 2439-2440 (2015).
48. J. A. Woyach, R. R. Furman, T.-M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H.-H. Li, S. M. Steggerda, M. Versele, S. S. Dave, J. Zhang, A. S. Yilmaz, S. M. Jaglowski, K. A. Blum, A. Lozanski, G. Lozanski, D. F. James, J. C. Barrientos, P. Lichter, S. Stilgenbauer, J. J. Buggy, B. Y. Chang, A. J. Johnson, J. C. Byrd, Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286-2294 (2014).
49. D. Chiron, M. Di Liberto, P. Martin, X. Huang, J. Sharman, P. Blecua, S. Mathew, P. Vijay, K. Eng, S. Ali, A. Johnson, B. Chang, S. Ely, O. Elemento, C. E. Mason, J. P. Leonard, S. Chen-Kiang, Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discovery 4, 1022-1035 (2014).
50. B. M. William, N. R. Bongu, M. Bast, R. G. Bociek, P. J. Bierman, J. M. Vose, J. O. Armitage, The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev. Bras. Hematol. Hemoter. 35, 189-191 (2013).
51. M. J. Maurer, H. Ghesquières, J.-P. Jais, T. E. Witzig, C. Haioun, C. A. Thompson, R. Delarue, I. N. Micallef, F. Peyrade, W. R. Macon, T. Jo Molina, N. Ketterer, S. I. Syrbu, O. Fitoussi, P. J. Kurtin, C. Allmer, E. Nicolas-Virelizier, S. L. Slager, T. M. Habermann, B. K. Link, G. Salles, H. Tilly, J. R. Cerhan, Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066-1073 (2014).
52. M. G. Bouwhuis, S. Suciu, S. Collette, S. Aamdal, W. H. Kruit, L. Bastholt, U. Stierner, F. Sales, P. Patel, C. J. Punt, M. Hernberg, A. Spatz, T. L. ten Hagen, J. Hansson, A. M. Eggermont; EORTC Melanoma Group and the Nordic Melanoma, Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J. Natl. Cancer Inst. 101, 869-877 (2009).
53. A. Giobbie-Hurder, R. D. Gelber, M. M. Regan, Challenges of guarantee-time bias. J. Clin. Oncol. 31, 2963-2969 (2013).
54. E. Bohers, P. J. Viailly, S. Dubois, P. Bertrand, C. Maingonnat, S. Mareschal, P. Ruminy, J.-M. Picquenot, C. Bastard, F. Desmots, T. Fest, K. Leroy, H. Tilly, F. Jardin, Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica 100, e280-e284 (2015).
55. D. Ennishi, C. Hoffer, H. Shulha, A. Mottok, P. Farinha, F. C. Chan, B. Meissner, M. Boyle, S. Ben-Neriah, R. D. Morin, M. A. Marra, K. J. Savage, L. H. Sehn, J. M. Connors, C. Steidl, D. W. Scott, R. D. Gascoyne, Clinical significance of genetic aberrations in diffuse large B cell lymphoma. Blood 124, 703 (2014).
56. R. Kridel, L. H. Sehn, R. D. Gascoyne, Pathogenesis of follicular lymphoma. J. Clin. Invest. 122, 3424-3431 (2012).
57. S. Montoto, J. Fitzgibbon, Transformation of indolent B-cell lymphomas. J. Clin. Oncol. 29, 1827-1834 (2011).
58. J. W. Friedberg, Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am. Soc. Hematol. Educ. Program 2011, 498-505 (2011).
59. A. P. Rapoport, J. M. Rowe, P. A. Kouides, R. A. Duerst, C. N. Abboud, J. L. Liesveld, C. H. Packman, S. Eberly, M. Sherman, M. A. Tanner, One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J. Clin. Oncol. 11, 2351-2361 (1993).
60. P. A. Hamlin, A. D. Zelenetz, T. Kewalramani, J. Qin, J. M. Satagopan, D. Verbel, A. Noy, C. S. Portlock, D. J. Straus, J. Yahalom, S. D. Nimer, C. H. Moskowitz, Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102, 1989-1996 (2003).
61. A. A. Alizadeh, A. J. Gentles, A. J. Alencar, C. L. Liu, H. E. Kohrt, R. Houot, M. J. Goldstein, S. Zhao, Y. Natkunam, R. H. Advani, R. D. Gascoyne, J. Briones, R. J. Tibshirani, J. H. Myklebust, S. K. Plevritis, I. S. Lossos, R. Levy, Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 118, 1350-1358 (2011).
62. L. M. Rimsza, G. Wright, M. Schwartz, W. C. Chan, E. S. Jaffe, R. D. Gascoyne, E. Campo, A. Rosenwald, G. Ott, J. R. Cook, R. R. Tubbs, R. M. Braziel, J. Delabie, T. P. Miller, L. M. Staudt, Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin. Cancer Res. 17, 3727-3732 (2011).
63. S. H. Swerdlow, E. Campo, N. L. Harris, E. S. Jaffe, S. A. Pileri, H. Stein, J. Thiele, J. W. Vardiman, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition (IARC Press, 2008).
64. A. D. Zelenetz, L. I. Gordon, W. G. Wierda, J. S. Abramson, R. H. Advani, C. B. Andreadis, N. Bartlett, J. C. Byrd, M. S. Czuczman, L. E. Fayad, R. I. Fisher, M. J. Glenn, N. L. Harris, R. T. Hoppe, S. M. Horwitz, C. R. Kelsey, Y. H. Kim, S. Krivacic, A. S. LaCasce, A. Nademanee, P. Porcu, O. Press, R. Rabinovitch, N. Reddy, E. Reid, A. A. Saad, L. Sokol, L. J. Swinnen, C. Tsien, J. M. Vose, J. Yahalom, N. Zafar, M. Dwyer, H. Sundar, National Comprehensive Cancer Network, Non-Hodgkin's lymphomas, version 4.2014. J. Natl. Compr. Cancer Network 12, 1282-1303 (2014).
65. L. Pasqualucci, G. Bhagat, M. Jankovic, M. Compagno, P. Smith, M. Muramatsu, T. Honjo, H. C. Morse III, M. C. Nussenzweig, R. Dalla-Favera, AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 40, 108-112 (2008).
66. J. M. Spence, A. Abumoussa, J. P. Spence, W. R. Burack, Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions. J. Immunol. 193, 4888-4894 (2014).
67. A. M. Newman, S. V. Bratman, H. Stehr, L. J. Lee, C. L. Liu, M. Diehn, A. A. Alizadeh, FACTERA: A practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics 30, 3390-3393 (2014).
68. M. Giraud, M. Salson, M. Duez, C. Villenet, S. Quief, A. Caillault, N. Grardel, C. Roumier, C. Preudhomme, M. Figeac, Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing. BMC Genomics 15, 409 (2014).
69. R. D. Morin, N. A. Johnson, T. M. Severson, A. J. Mungall, J. An, R. Goya, J. E. Paul, M. Boyle, B. W. Woolcock, F. Kuchenbauer, D. Yap, R. K. Humphries, O. L. Griffith, S. Shah, H. Zhu, M. Kimbara, P. Shashkin, J. F. Charlot, M. Tcherpakov, R. Corbett, A. Tam, R. Varhol, D. Smailus, M. Moksa, Y. Zhao, A. Delaney, H. Qian, I. Birol, J. Schein, R. Moore, R. Holt, D. E. Horsman, J. M. Connors, S. Jones, S. Aparicio, M. Hirst, R. D. Gascoyne, M. A. Marra, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
70. L. Pasqualucci, V. Trifonov, G. Fabbri, J. Ma, D. Rossi, A. Chiarenza, V. A. Wells, A. Grunn, M. Messina, O. Elliot, J. Chan, G. Bhagat, A. Chadburn, G. Gaidano, C. G. Mullighan, R. Rabadan, R. Dalla-Favera, Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830-837 (2011).
71. S. Dubois, P. J. Viailly, S. Mareschal, E. Bohers, P. Bertrand, P. Ruminy, C. Maingonnat, J. P. Jais, P. Peyrouze, M. Figeac, T. J. Molina, F. Desmots, T. Fest, C. Haioun, T. Lamy, C. Copie-Bergman, J. Briere, T. Petrella, D. Canioni, B. Fabiani, B. Coiffier, R. Delarue, F. Peyrade, A. Bosly, M. Andre, N. Ketterer, G. Salles, H. Tilly, K. Leroy, F. Jardin, Next generation sequencing in diffuse large B cell lymphoma highlights molecular divergence and therapeutic opportunities: A LYSA study. Clin. Cancer Res. 22, 2919-2928 (2016).
72. E. Bohers, S. Mareschal, P. Bertrand, P. J. Viailly, S. Dubois, C. Maingonnat, P. Ruminy, H. Tilly, F. Jardin, Activating somatic mutations in diffuse large B-cell lymphomas: Lessons from next generation sequencing and key elements in the precision medicine era. Leuk. Lymphoma 56, 1213-1222 (2015).
73. S. Mareschal, S. Dubois, P.-J. Viailly, P. Bertrand, E. Bohers, C. Maingonnat, J.-P. Jaïs, B. Tesson, P. Ruminy, P. Peyrouze, C. Copie-Bergman, T. Fest, T. Jo Molina, C. Haioun, G. Salles, H. Tilly, T. Lecroq, K. Leroy, F. Jardin, Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer 55, 251-267 (2016).
74. M. Faham, J. Zheng, M. Moorhead, V. E. H. Carlton, P. Stow, E. Coustan-Smith, C.-H. Pui, D. Campana, Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120, 5173-5180 (2012).
75. K. Hirata, K. Kobayashi, K.-P. Wong, O. Manabe, A. Surmak, N. Tamaki, S.-C. Huang, A semi-automated technique determining the liver standardized uptake value reference for tumor delineation in FDG PET-CT. PLOS ONE 9, e105682 (2014).
76. A. Rosset, L. Spadola, O. Ratib, OsiriX: An open-source software for navigating in multidimensional DICOM images. J. Digit. Imaging 17, 205-216 (2004).
77. B. D. Cheson, The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol. Oncol. Clin. North Am. 21, 841-854 (2007).
78. D. W. Scott, A. Mottok, D. Ennishi, G. W. Wright, P. Farinha, S. Ben-Neriah, R. Kridel, G. S. Barry, C. Hother, P. Abrisqueta, M. Boyle, B. Meissner, A. Telenius, K. J. Savage, L. H. Sehn, G. W. Slack, C. Steidl, L. M. Staudt, J. M. Connors, L. M. Rimsza, R. D. Gascoyne, Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J. Clin. Oncol. 33, 2848-2856 (2015).
79. G. Lenz, G. Wright, S. S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N. Goldschmidt, J. Iqbal, J. Vose, M. Bast, K. Fu, D. D. Weisenburger, T. C. Greiner, J. O. Armitage, A. Kyle, L. May, R. D. Gascoyne, J.M. Connors, G. Troen, H. Holte, S. Kvaloy, D. Dierickx, G. Verhoef, J. Delabie, E. B. Smeland, P. Jares, A. Martinez, A. Lopez-Guillermo, E. Montserrat, E. Campo, R. M. Braziel, T. P. Miller, L. M. Rimsza, J. R. Cook, B. Pohlman, J. Sweetenham, R. R. Tubbs, R. I. Fisher, E. Hartmann, A. Rosenwald, G. Ott, H. K. Muller-Hermelink, D. Wrench, T. A. Lister, E. S. Jaffe, W. H. Wilson, W. C. Chan, L. M. Staudt; Lymphoma/Leukemia Molecular Profiling Project, Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313-2323 (2008).
80. J. R. Anderson, D. S. Neuberg, Analysis of outcome by response flawed. J. Clin. Oncol. 23, 8122-8123 (2005).
81. V. Ribrag, J.-C. Soria, J.-M. Michot, A. Schmitt, S. Postel-Vinay, F. Bijou, B. Thomson, H. Keilhack, S. J. Blakemore, L. Reyderman, P. Kumar, G. Fine, A. McDonald, P. T. Ho, A. Italiano, Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): Preliminary safety and activity in relapsed or refractory non-hodgkin lymphoma (NHL) patients. Blood 126, 473 (2015).
82. M. T. McCabe, H. M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G. S. Van Aller, Y. Liu, A. P. Graves, A. Della Pietra III, E. Diaz, L. V. LaFrance, M. Mellinger, C. Duquenne, X. Tian, R. G. Kruger, C. F. McHugh, M. Brandt, W. H. Miller, D. Dhanak, S. K. Verma, P. J. Tummino, C. L. Creasy, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).